Gilead Sciences (GILD) to Acquire All Remaining Rights to Potential First-in-Class Immunotherapy GS-1811 From Jounce Therapeutics (JNCE) Dec 27, 2022 04:30PM
Gilead To Acquire All Remaining Rights To Potential First-In-Class Immunotherapy GS-1811 From Jounce Therapeutics Dec 27, 2022 04:30PM
Gilead to Acquire All Remaining Rights to Potential First-in-Class Immunotherapy GS-1811 From Jounce Therapeutics Dec 27, 2022 04:30PM
IMV Inc. Announces Third Quarter 2021 Financial and Operational Update Nov 10, 2021 05:05PM
Jounce Therapeutics, Inc. (Nasdaq: JNCE) to Ring the Nasdaq Stock Market Closing Bell Jan 26, 2018 11:57AM


Jun 21, 2017 08:30AM Loncar Cancer Immunotherapy Index Conducts Semi-Annual Rebalance
May 9, 2017 08:00AM Jounce Therapeutics Reports First Quarter 2017 Financial Results